11月 2025
- 首頁
- TAPI
11月 2025TAPI的市場佔有率分析
At TAPI, our Contract Development and Manufacturing Organization (CDMO) capabilities are designed to address the complex challenges of developing oligonucleotide APIs. These advanced modalities require specialized expertise to ensure quality, regulatory compliance, and process efficiency from early-stage development to full-scale production. Our proven track record in overcoming technical challenges enables us to provide high-quality, flexible solutions […]
TAPI(包含公司地區)
查看更多網站流量與參與度資訊- tapi.com
TAPI截至 11月 2025 的總收入為 25M - 50M
TAPI 熱門網域產生的總收入
TAPI 熱門網域 3 年內的總收入
TAPI 熱門網域的總收入
TAPI的熱門網域總造訪量
了解TAPI市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
TAPI的熱門網域平均造訪時長
分析TAPI參與度指標。
過去 3 個月平均造訪時長
子公司細目
TAPI的熱門網域平均頁面瀏覽量
了解TAPI如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自TAPI
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Teva Pharmaceutical Industries Ltd. launches TAPI.Teva Pharmaceutical Industries, a prominent player in the global pharmaceutical sector, has announced its plans to divest its active pharmaceutical ingredient (API) division, known as TAPI (Teva Active Pharmaceutical Ingredients).
2月 14, 2024閱讀更多
新聞Teva Pharmaceutical Industries Ltd. launched biosimilar Truxima injection on May 1st '20.For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis.
8月 8, 2022閱讀更多
新聞Teva Pharmaceutical Industries Ltd. has issues with three patents on its Ajovy migraine drug, though six other patents on the treatment.The Hard Rock trademarks are “famous among the general consuming people of the United States as a whole, ... Teva Pharmaceutical Industries Ltd. won a U.S. appeals court ruling that upheld three patents on its Ajovy migraine drug, though six other patents on the treatment were ruled invalid.
7月 8, 2021閱讀更多
查看所有TAPI信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。